A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients

Antiviral Therapy

Volumn 14, Issue 7, 2009, Pages 923-929

  Bouillon Pichault, Marion ^a,b,c,d   Jullien, Vincent ^a,b,c   Piketty, Christophe ^a,b,e   Viard, Jean Paul ^b,d,f   Morini, Jean Pierre ^b,c   Chhun, Stéphanie ^a,b,c   Krivine, Anne ^b,c   Salmon, Dominique ^a,b,c   Dupin, Nicolas ^a,b,c   Weiss, Laurence ^a,b,e   Lortholary, Olivier ^a,b,f   Pons, Gérard ^a,b,c   Launay, Odile ^a,b,c,d   Treluyer, Jean Marc ^a,b,c,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Institut Cochin   (France)

^d EA   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG EXPOSURE; DRUG MONITORING; EVENING DOSAGE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MORNING DOSAGE; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY;

ADOLESCENT; ADULT; AGED; BODY WEIGHT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; POPULATION SURVEILLANCE; PYRIMIDINONES; TABLETS;

EID: 72249122367     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1414     Document Type: Article

References (23)

1. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63:769-802. (Pubitemid 36432083)
2. Crommentuyn KM, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005; 60:378-389. (Pubitemid 41428469)
3. Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005; 24:874-879. (Pubitemid 41475921)
4. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:350-359. (Pubitemid 36070384)
5. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18:1305-1310. (Pubitemid 38822709)
6. Boffito M, Arnaudo I, Raiteri R, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002; 16:2081-2083. (Pubitemid 35205274)
7. van der Leur MR, Burger DM, la Porte CJ, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit 2006; 28:650-653.
8. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401-410. (Pubitemid 46555374)
9. Beal SL, Sheiner LB. NONMEM user's guide. San Francisco: NONMEM Project Group, University of California at San Francisco 1991.
10. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189:265-272. (Pubitemid 38147251)
11. Dailly E, Allavena C, Raffi F, Jolliet P. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. Br J Clin Pharmacol 2005; 60:32-34. (Pubitemid 40942778)
12. Dailly E, Reliquet V, Raffi F, Jolliet P. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 61:153-156. (Pubitemid 40674748)
13. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004; 75:310-323. (Pubitemid 38471556)
14. van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. Br J Clin Pharmacol 2005; 59:398-404. (Pubitemid 40523883)
15. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391. (Pubitemid 32268418)
16. Hurst M, Faulds D. Lopinavir. Drugs 2000; 60:1371-1379.
17. de Requena DG, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004; 20:275-278. (Pubitemid 38429399)
18. Hoefnagel JG, van der Lee MJ, Koopmans PP, et al. The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. AIDS 2006; 20:1069-1071.
19. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir- containing regimens. J Acquir Immune Defic Syndr 2003; 33:594-600. (Pubitemid 36975846)
20. de Requena DG, Blanco F, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS 2003; 17:443-445. (Pubitemid 37205697)
21. Dailly E, Gagnieu MC, Allavena C, Raffi F, Jolliet P. No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach. Ther Drug Monit 2005; 27:782-784. (Pubitemid 44391735)
22. Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004; 48:4256-4262. (Pubitemid 39434884)
23. Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol 2007; 47:970-977. (Pubitemid 47094097)